Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925544 · ClinicalTrials.gov registry record · Phase 2
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
A Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma, sponsored by Stanford University.
- Active
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04925544 is a Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 13 participants, below the 183-participant average among 4 other Nasopharyngeal Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04925544, a Phase 2 study of Nasopharyngeal Cancer and Epstein-Barr Virus Related Carcinoma, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
Conditions Studied
Interventions
- DRUG VK-2019
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2027-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925544
The ClinicalTrials.gov registry entry for NCT04925544 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 4 other Nasopharyngeal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Nasopharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which VK-2019 is the first listed.
NCT04925544 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04925544 about?
NCT04925544 is a clinical study titled "Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies". To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal carcinoma (NPC) for whom there is no other standard treatment available
What is the current status of trial NCT04925544?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-01-25. Estimated completion is 2027-06-17.
What conditions does trial NCT04925544 study?
This clinical trial studies the following conditions: Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma.
What interventions are being tested in trial NCT04925544?
The interventions under investigation include: VK-2019 (DRUG).
Who is sponsoring clinical trial NCT04925544?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04925544 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasopharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
RECRUITING · NA
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
COMPLETED
Explore more on PlainTrial
Nasopharyngeal Cancer
All registered trials for this condition
Epstein-Barr Virus Related Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.